Hanmi Pharm. Co., Ltd.
Financials
Valuation Metrics
Hanmi Pharm. Co., Ltd.'s Market Cap is ₩5.4T. At end of 2025 it was ₩5.8T. Ranked #91 of 2,405 in KR market (top 4%), #85 of 778 on KOSPI (top 11%), #7 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 3%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 5.43T KRW | KR#91/2,405 Sec#7/231 |
| Revenue | 1.66T KRW | KR#294/2,405 Sec#9/231 |
| Net Income | 234.64B KRW | KR#127/2,405 Sec#4/231 |
| Total Assets | 2.33T KRW | KR#279/2,405 Sec#10/231 |
| Net Assets | 1.59T KRW | KR#212/2,405 Sec#8/231 |
| Employees | 2,388 | KR#123/2,405 Sec#3/231 |
| Value | ||
| P/E | 23.12x | KR#1,252/2,405 Sec#75/231 |
| P/B | 3.41x | KR#2,175/2,405 Sec#182/231 |
| PEG | 0.22x | KR#596/2,405 Sec#35/231 |
| P/S | 3.28x | KR#2,032/2,405 Sec#127/231 |
| EV/EBITDA | 17.41x | KR#975/2,405 Sec#56/231 |
| FCF Yield | 2.40% | KR#1,041/2,405 Sec#68/231 |
| Profitability | ||
| ROE | 14.77% | KR#335/2,405 Sec#23/231 |
| ROA | 10.05% | KR#274/2,405 Sec#21/231 |
| Op. Margin | 19.52% | KR#171/2,405 Sec#17/231 |
| Revenue Growth | 12.93% | KR#759/2,405 Sec#73/231 |
| Earnings Growth | 106.35% | KR#377/2,405 Sec#25/231 |
| Financial Health | ||
| Debt Ratio | 46.86% | KR#913/2,405 Sec#104/231 |
| Total Debt | 408.09B KRW | KR#348/2,405 Sec#14/231 |
| FCF | 130.05B KRW | KR#151/2,405 Sec#8/231 |
| Cash | 209.04B KRW | KR#259/2,405 Sec#9/231 |
| Current Ratio | 1.82x | KR#959/2,405 Sec#106/231 |
| Net Debt/EBITDA | 0.62x | KR#692/2,405 Sec#42/231 |
| Dividend | ||
| Div. Yield | 0.47% | KR#1,286/2,405 Sec#80/231 |
| Div. Growth | 60.00% | KR#200/2,405 Sec#7/231 |
| Performance | ||
| 1Y Return | -0.35% | KR#614/2,405 Sec#33/231 |
| 1M Return | -16.30% | KR#1,657/2,405 Sec#164/231 |
| From 52W High | -34.54% | KR#568/2,405 Sec#36/231 |
| 1Y MDD | -50.24% | KR#969/2,405 Sec#76/231 |
| Trading | ||
| Volume | 113,496 shares | KR#580/2,405 Sec#59/231 |
| Trading Value | 47.87B KRW | KR#49/2,405 Sec#3/231 |
| Foreign Own. | 13.74% | KR#351/2,405 Sec#23/231 |
| Per Share | ||
| EPS | 18,315 KRW | KR#56/2,405 Sec#3/231 |
| BPS | 124,041 KRW | KR#119/2,405 Sec#5/231 |
Company Info
Hanmi Pharmaceutical was established in 2010 through a spin-off of its pharmaceutical manufacturing and sales division, comprising three domestic and international subsidiaries. It produces Rosuzet, Amozaltan, and Esomezol, while Hanmi Fine Chemical exports cephalosporin-based antibiotics globally, and Beijing Hanmi Pharmaceutical Co., Ltd. sells various products. The company focuses on innovative new drug development, having acquired numerous patents by 2025, and is optimizing manufacturing processes and saving energy to reduce greenhouse gas emissions by 30% by 2030. Hanmi Pharmaceutical is headquartered in Hwaseong-si, Gyeonggi-do.